CRDF Q3 2025 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$120,000-27.3% YoY

Gross Profit

$120,000100.0% margin

Operating Income

-$12M-9978.3% margin

Net Income

-$11M-9381.7% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

-0.8%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$64M

Total Liabilities

$15M

Stockholders' Equity

$49M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$120,000	$165,000	-27.3%
Gross Profit	$120,000	-$9M	+101.3%
Operating Income	-$12M	-$13M	+5.0%
Net Income	-$11M	-$12M	+5.0%